Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,998
Views
1
CrossRef citations to date
0
Altmetric
Brief Report

Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials

Bianca Maria Piraccinia Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6537-9689View further author information
ORCID Icon,
Manabu Ohyamab Department of Dermatology, Kyorin University, Tokyo, JapanView further author information
,
Brittany Craiglowc Department of Dermatology, Yale School of Medicine, New Haven, CT, USAView further author information
,
Anthony Bewleyd Department of Dermatology, Barts Health NHS Trust, London, and Queen Mary University of London, London, UKView further author information
,
Yuxin Dinge Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Yun-Fei Chene Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Yves Dutronce Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Evangeline Piercee Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Frederick Durande Eli Lilly and Company, Indianapolis, IN, USAView further author information
&
Arash Mostaghimif Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAView further author information
 show all
Article: 2227299 | Received 28 Mar 2023, Accepted 08 Jun 2023, Published online: 28 Jun 2023

References

  • Liu LY, King AB, Craiglow GB. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):1–4.e3. doi: 10.1016/j.jaad.2016.04.035.
  • Toussi A, Barton VR, Le ST, et al. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162–175. doi: 10.1016/j.jaad.2020.06.047.
  • Messenger A, Harries M. Baricitinib in alopecia areata. N Engl J Med. 2022;386(18):1751–1752. doi: 10.1056/NEJMe2203440.
  • King B, Ohyama M, Kwon O. et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699. doi: 10.1056/NEJMoa2110343.
  • Piraccini BM, Ohyama M, Craiglow B, et al. The contribution of hair regrowth to health-related quality of life improvement in patients with alopecia areata treated with baricitinib or placebo. Paper presented at: World Congress for Hair Research 2022; 2022 November 18–21; Melbourne, Australia.
  • Olsen EA, Hordinsky MK, Price VH. et al. Alopecia areata investigational assessment guidelines–part II. National alopecia areata foundation. J Am Acad Dermatol. 2004;51(3):440–447. doi: 10.1016/j.jaad.2003.09.032.
  • Wyrwich KW, Kitchen H, Knight S, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702–709. doi: 10.1111/bjd.18883.
  • King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847–853. doi: 10.1016/j.jaad.2021.05.050.
  • Chren MM. The skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231–236, xiii. doi: 10.1016/j.det.2011.11.003.
  • Chren MM. SKINDEX-16 for alopecia areata (SKINDEX-16 for AA). 2018. Available from: https://eprovide.mapi-trust.org/instruments/skindex-16-for-alopecia-areata#contact_and_conditions_of_use.
  • Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29. doi: 10.1186/1477-7525-1-29.
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
  • Winnette R, Banerjee A, Sikirica V, et al. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J Eur Acad Dermatol Venereol. 2022;36(4):602–609. doi: 10.1111/jdv.17909.
  • Aldhouse NVJ, Kitchen H, Knight S, et al. You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed”: a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76. doi: 10.1186/s41687-020-00240-7.
  • Edson-Heredia E, Cutts K, Bethesda E, et al. The relationship between the degree of scalp hair loss and health-related quality of life among patients with alopecia areata. J Am Acad Dermatol. 2022;87(3):AB120. Suppl AB120, doi: 10.1016/j.jaad.2022.06.512.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.